| Zhang, Hong |
NCT03431428: Comparison of Short-term Efficacy and Long-term Prognosis for Reduction Surgery and Radical Resection in Almost-cCR Rectal Cancer Patients |
|
|
| Recruiting | 3 | 477 | RoW | transanal surgery, Miles surgery, Preoperative chemoradiotherapy | Zhang Rui | Almost-cCR, Surgery, Rectal Cancer | 01/20 | 12/22 | | |
| Completed | 3 | 1412 | RoW | Injection of recombinant human tissue plasminogen kinase derivatives, Reteplase, brand name: Ruitongli, r-PA, Recombinant human tissue plasminogen activator, Alteplase, brand name: Actilyse, rt-PA | Angde Biotech Pharmaceutical Co., Ltd., Beijing Tiantan Hospital | Acute Ischemic Stroke | 06/23 | 06/23 | | |
NCT05629390: Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study |
|
|
| Completed | 3 | 163 | RoW | Lotilaner, TP-03, S-Misoxam, Vehicle Control | LianBio LLC | Blepharitis | 09/23 | 04/24 | | |
NCT05745259: Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-Ⅲ） |
|
|
| Recruiting | 3 | 1630 | RoW | Alteplase, rt-PA, Tenecteplase, TNK-tPA | Beijing Tiantan Hospital, Jiangsu FENG HUA Biotech Pharmaceutical Co., Ltd, The Place Pharmaceutical(Jiangsu) Co., Ltd | Acute Ischemic Stroke | 11/23 | 03/24 | | |
TaLaR-02, NCT05984485: The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer |
|
|
| Recruiting | 3 | 766 | RoW | neoadjuvant chemotherapy plus total mesorectal excision, total mesorectal excision | Sun Yat-sen University | Rectal Cancer | 07/28 | 07/28 | | |
NCT05702489: A Study to Evaluate the Efficacy and Safety of ZX-7101A Tablets in Adults with Uncomplicated Influenza |
|
|
| Completed | 2/3 | 900 | RoW | ZX-7101A | Nanjing Zenshine Pharmaceuticals | Influenza, Human | 05/23 | 10/23 | | |
NCT04398459: The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia |
|
|
| Active, not recruiting | 2 | 18 | RoW | Ibrutinib, BTK inhibitor | Institute of Hematology & Blood Diseases Hospital, China | Refractory/Relapsed Autoimmune Hemolytic Anemia | 12/24 | 06/25 | | |
NCT05292196: A Phase II Clinical Trial of TQC3721 Suspension for Inhalation |
|
|
| Recruiting | 2 | 460 | RoW | TQC3721 suspension for inhalation, TQC3721 suspension placebo for inhalation | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Obstructive Pulmonary Disease (COPD) | 01/24 | 05/24 | | |
NCT06670352: Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN |
|
|
| Recruiting | 2 | 80 | RoW | Placebo, HSK39297 50mgBID, HSK39297 100mgBID, HSK39297 200mgQD | Haisco Pharmaceutical Group Co., Ltd. | IgA Nephropathy (IgAN) | 11/25 | 03/26 | | |
BID-PERAL, NCT04423367: Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment |
|
|
| Completed | 2 | 18 | RoW | bortezomib/dexamethasone | Institute of Hematology & Blood Diseases Hospital, China | Acquired Pure Red Cell Aplasia | 07/24 | 09/24 | | |
NCT05660785: Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia |
|
|
| Active, not recruiting | 2 | 54 | RoW | Herombopag, Cyclosporine A | Institute of Hematology & Blood Diseases Hospital, China, Jiangsu Hengrui Pharmaceuticals Co.,Ltd | Non Severe Aplastic Anemia, Untreated | 01/25 | 05/25 | | |
NCT06687174: Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN) |
|
|
| Not yet recruiting | 2 | 72 | RoW | MY008211A tablets, MY008211A tablets matched placebo | Wuhan Createrna Science and Technology Co., Ltd | IgA Nephropathy (IgAN) | 06/26 | 01/28 | | |
NCT06760182: Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic Rhinitis |
|
|
| Not yet recruiting | 2 | 168 | RoW | TQH2722 injection, TQH2722 Placebo | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Seasonal Allergic Rhinitis | 06/25 | 08/25 | | |
NCT04688736: Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions. |
|
|
| Recruiting | 2 | 6642 | RoW | Placebo, Chlorpheniramine | Institute of Hematology & Blood Diseases Hospital, China | Allergic Transfusion Reaction | 12/25 | 06/26 | | |
NCT06774664: A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases |
|
|
| Not yet recruiting | 1/2 | 99 | RoW | SCTC21C | Sinocelltech Ltd. | IgA Nephropathy | 09/27 | 03/29 | | |
NCT04481841: Head Yuanshi Dian Therapy in Burning Mouth Syndrome |
|
|
| Recruiting | 1 | 290 | RoW | oryzanol + vitamin B2 (riboflavin) + vitamin E, head yuanshi dian therapy | Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Hospital of TCM, Guiyang Hospital of Stomatology | Burning Mouth Syndrome, Oral Mucosa Disease | 02/22 | 05/22 | | |
NCT06101316: A Bridging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB06-036 in Healthy Subjects in China |
|
|
| Recruiting | 1 | 12 | RoW | CB06-036 | Shanghai Zhimeng Biopharma, Inc. | Healthy Volunteers | 10/23 | 12/23 | | |
NCT06216041: To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects |
|
|
| Recruiting | 1 | 138 | RoW | IMM-H014, Placebo, IMM-H014 ( FE), Placebo ( FE) | Changchun Intellicrown Pharmaceutical Co. LTD | Nonalcoholic Steatohepatitis (NASH) | 07/24 | 12/24 | | |
NCT06160895: A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects |
|
|
| Completed | 1 | 40 | RoW | TQ-A3334 tablets, TQ-A3334 placebo tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatitis B | 06/24 | 08/24 | | |
NCT06427681: An Relative Bioavailability Study of BH006 for Injection in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 40 | NA | BH006 for injection, Fosaprepitant for injection+Palonosetron hydrochloride injection, EMEND®+PALONOSETRON | Zhuhai Beihai Biotech Co., Ltd | Bioavailability | 09/24 | 12/24 | | |
| Not yet recruiting | 1 | 18 | NA | AP303 150μg, AP303 300μg, Placebo 150μg, Placebo 300μg | Alebund Pharmaceuticals | Diabetic Kidney Disease | 01/25 | 01/25 | | |
| Completed | N/A | 980 | RoW | Rotational Atherectomy | Beijing Anzhen Hospital, BSC International Medical Trading (Shanghai) Co., Ltd. | Coronary Artery Disease | 12/20 | 01/22 | | |
UltraFuture I, NCT05498740: Post-marketing Study in Femoral Popliteal Artery of Drug Coated Balloon Used for Treatment of Lower Limb Ischemia |
|
|
| Recruiting | N/A | 200 | RoW | Drug eluting Balloon | Zhejiang Zylox Medical Device Co., Ltd. | Peripheral Arterial Disease (PAD) | 12/22 | 12/24 | | |
NCT05608980: 0.01% Hypochlorous Acid in the Treatment of Blepharitis |
|
|
| Recruiting | N/A | 100 | RoW | 0.01% hypochlorous acid, 0.01%HOCI, Placebo | Eye & ENT Hospital of Fudan University, ShuGuang Hospital | Blepharitis | 12/22 | 05/23 | | |
NCT05685966: Retrospective Study of COVID-19 on Reproductive Function |
|
|
| Recruiting | N/A | 400 | RoW | no intervention | Jinling Hospital, China | COVID-19 | 03/23 | 01/24 | | |
NCT04852406: Protocol-based Management and Perioperative Outcomes in Patients With Chronic Antithrombotic Therapy |
|
|
| Recruiting | N/A | 526 | RoW | Protocol-based management of perioperative antithrombotic therapy, Protocol-based management, Routine management of perioperative antithrombotic therapy, Routine management | Peking University First Hospital | Antithrombotic Therapy, Perioperative Care, Perioperative Outcomes | 12/23 | 01/24 | | |
NCT05685992: Novel Coronavirus Infection and Reproductive Function |
|
|
| Recruiting | N/A | 400 | RoW | no intervention | Jinling Hospital, China | COVID-19 Infection | 01/24 | 01/24 | | |
CSILS, NCT04527861: Oncologic Outcomes of Single-incision Versus Conventional Laparoscopic Surgery for Colorectal Cancer |
|
|
| Recruiting | N/A | 710 | RoW | Single-incision Laparoscopic Surgery, SILS, Conventional Laparoscopic Surgery, CLS | Ruijin Hospital, Dongfang Hospital Affiliated to Tongji University, Fudan University, Changhai Hospital, Shengjing Hospital, RenJi Hospital, Liaoning Cancer Hospital & Institute, Zhejiang Provincial People's Hospital, Shandong Provincial Hospital, The General Hospital of Western Theater Command, Shanghai Jiao Tong University School of Medicine | Colorectal Cancer, Colon Cancer, Rectal Cancer | 04/24 | 04/29 | | |
NCT04645810: A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence |
|
|
| Recruiting | N/A | 12 | US | High-Dose-Rate Brachytherapy | University of Rochester | Prostate Cancer, HDR | 05/26 | 05/27 | | |
SCDB, NCT06422845: Peripheral Scoring Drug-coated Balloon in the Treatment of Hemodialysis Arteriovenous Fistula Stenosis |
|
|
| Recruiting | N/A | 328 | RoW | Dissolve AV Peripheral Scoring Drug-coated Balloon, Scoring Drug-coated Balloon | DK Medical Technology (Suzhou) Co., Ltd. | Arteriovenous Fistula Stenosis | 07/27 | 07/27 | | |
| Recruiting | N/A | 1114 | RoW | TaTME, Transanal TME, LpTME, Laparoscopic TME | Sun Yat-sen University, Peking Union Medical College Hospital, The First Hospital of Jilin University, RenJi Hospital, Shengjing Hospital, The Second People's Hospital of Yibin, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, Nanchong Central Hospital, Zunyi Medical College, The First Affiliated Hospital of University of South China, Xinqiao Hospital, Nanfang Hospital, Southern Medical University, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, Affiliated Hospital of Guangdong Medical University, The Third Xiangya Hospital of Central South University | Rectal Neoplasms Malignant, Surgery | 07/26 | 07/26 | | |
| Recruiting | N/A | 10000 | RoW | Installation or registration of smartphone application | Chinese Alliance Against Lung Cancer | Solitary Pulmonary Nodule | 10/25 | 10/25 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
| Not yet recruiting | N/A | 550 | RoW | lymph node dissection, Fluorescence-guided laparoscopic surgery, Radical operation for rectal cancer and sigmoid Cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Fudan University, Fujian Province Tumor Hospital, Guangdong Provincial People's Hospital, Shengjing Hospital, Affiliated Hospital of Qinghai University, Hebei Medical University Fourth Hospital, The Second Affiliated Hospital of Harbin Medical University, Jiangxi Provincial Cancer Hospital, The First Hospital of Jilin University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Shanxi Province Cancer Hospital, Nanfang Hospital, Southern Medical University, Second People's Hospital of Yunnan Province, Binzhou Medical University, The First Affiliated Hospital of University of Science and Technology of China, First Affiliated Hospital of Chengdu Medical College, The Second People's Hospital of Yibin, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Colorectal Neoplasms, Fluorescence, Lymph Node Excision | 12/26 | 06/27 | | |
| Recruiting | N/A | 366 | Canada, RoW | | The George Institute, Peking University Institute of Nephrology | IgA Nephropathy, ESRD, Glomerulonephritis, Kidney Diseases | 07/27 | 07/27 | | |
| Wu, Lijun |
SMART, NCT06722586: Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia |
|
|
| Recruiting | 3 | 84 | RoW | Sirolimus, Rapamycin, mTOR inhibitor, Placebo | Peking University First Hospital, North China Pharmaceutical Co.,Ltd | Antiphospholipid (aPL)-positive, Thrombocytopaenia | 12/27 | 12/27 | | |
NCT05212051: Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active AS |
|
|
| Recruiting | 2 | 120 | RoW | JS005, Recombinant humanized anti-IL-17A monoclonal antibody injection, Placebo | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Active Ankylosing Spondylitis | 11/22 | 01/23 | | |
NCT05242588: Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA |
|
|
| Recruiting | 2 | 120 | RoW | JS005, Recombinant humanized anti-IL-17A monoclonal antibody injection, Placebo | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Non-radiographic Axial Spondyloarthritis | 04/23 | 06/23 | | |
NCT06250062: A Clinical Study of JS005 in Patients With Ankylosing Spondylitis |
|
|
| Recruiting | 2 | 261 | RoW | Recombinant humanized IL-17A Monoclonal Antibody（JS005）, Placebo（JS005） | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Ankylosing Spondylitis | 02/25 | 10/25 | | |
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus |
|
|
| Recruiting | 2 | 186 | RoW | Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Systemic Lupus Erythematosus, SLE | 08/25 | 05/26 | | |
NCT05998759: Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia |
|
|
| Recruiting | 2 | 296 | RoW | Telitacicept, recombinant human B lymphocyte stimulating factor receptor-Fc fusion protein, Recombinant Human B Lymphocyte(RC18), Tai'ai®, Placebo, Placebo control, control | Beijing Hospital, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial), Peking University People's Hospital, Peking University Third Hospital, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, Wuhan Union Hospital, China, Second Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The Affiliated Hospital of Inner Mongolia Medical University, First Hospital of China Medical University, Shandong Provincial Hospital, Changhai Hospital, RenJi Hospital, Shanxi Bethune Hospital, West China Hospital, Institute of Hematology & Blood Diseases Hospital, China, Tianjin First Central Hospital, Tianjin Medical University General Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, The First People's Hospital of Yunnan | Connective Tissue Diseases, Thrombocytopenia | 12/25 | 12/25 | | |
NCT05247203: Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus |
|
|
| Completed | 1 | 92 | RoW | Telitacicept, RC18, standard therapy | RemeGen Co., Ltd. | Systemic Lupus Erythematosus | 10/23 | 11/23 | | |
| Recruiting | N/A | 116 | RoW | Leflunomide 10mg Tab, Prednisone Acetate, Placebos | Jiang lindi | Takayasu Arteritis | 12/22 | 12/22 | | |
| Li, Qin |
NCT05998759: Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia |
|
|
| Recruiting | 2 | 296 | RoW | Telitacicept, recombinant human B lymphocyte stimulating factor receptor-Fc fusion protein, Recombinant Human B Lymphocyte(RC18), Tai'ai®, Placebo, Placebo control, control | Beijing Hospital, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial), Peking University People's Hospital, Peking University Third Hospital, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, Wuhan Union Hospital, China, Second Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The Affiliated Hospital of Inner Mongolia Medical University, First Hospital of China Medical University, Shandong Provincial Hospital, Changhai Hospital, RenJi Hospital, Shanxi Bethune Hospital, West China Hospital, Institute of Hematology & Blood Diseases Hospital, China, Tianjin First Central Hospital, Tianjin Medical University General Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, The First People's Hospital of Yunnan | Connective Tissue Diseases, Thrombocytopenia | 12/25 | 12/25 | | |
NCT05777707: Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma |
|
|
| Recruiting | 1/2 | 89 | RoW | PD-1 blockade, Albumin paclitaxel, Carboplatin/Nedaplatin | Beijing Friendship Hospital | Esophageal Carcinoma, Neoadjuvant Immunotherapy | 12/23 | 12/24 | | |
NCT05247203: Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus |
|
|
| Completed | 1 | 92 | RoW | Telitacicept, RC18, standard therapy | RemeGen Co., Ltd. | Systemic Lupus Erythematosus | 10/23 | 11/23 | | |
NCT05265806: The Effects of Oxytocin Treatment on Social Touch |
|
|
| Completed | N/A | 180 | RoW | Intranasal oxytocin, Oxytocin intranasal spray, Oral oxytocin, Oxytocin lingual spray, Placebo, PLC | University of Electronic Science and Technology of China | Healthy | 03/22 | 05/22 | | |
| Recruiting | N/A | 2000 | RoW | | Peking Union Medical College Hospital | Anti Phospholipid Syndrome | 12/26 | 12/26 | | |
| Lai, Xun |
NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 3 | 85 | RoW | Pomalidomide, Dexamethasone | Qilu Pharmaceutical Co., Ltd. | Multiple Myeloma, Recurrent or Refractory | 06/22 | 12/23 | | |
NCT06082102: Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Compared to Placebo Plus R2 in r/r Marginal Zone Lymphoma |
|
|
| Recruiting | 3 | 324 | RoW | Orelabrutinib, Lenalidomide, Rituximab, Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Relapsed/Refractory Marginal Zone Lymphoma | 08/27 | 02/30 | | |
| Su, Heng |
ESPTTN, NCT06423235: Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules |
|
|
| Not yet recruiting | 4 | 426 | RoW | regular dose of JiRui® Prunella oral liquid, 2x regular dose of JiRui® Prunella oral liquid, regular dose of placebo, 2x regular dose of placebo | Xintian Pharmaceutical | Thyroid Nodule | 07/25 | 07/28 | | |
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 1500 | Europe, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Type 2 Diabetes | 08/25 | 08/25 | | |
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 07/25 | 07/27 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
NCT05593081: Multicenter Study of Fulminant Type 1 Diabetes in China |
|
|
| Recruiting | N/A | 240 | RoW | HLA | Second Xiangya Hospital of Central South University | Diabetes Mellitus, Type 1 | 12/27 | 12/27 | | |
NCT05498974: China Diabetes Type 1 Study (CD1S) by China Alliance for Type 1 Diabetes |
|
|
| Recruiting | N/A | 20000 | RoW | Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center | Second Xiangya Hospital of Central South University | Type1diabetes, Diabetes | 12/35 | 12/35 | | |
| Geng, Jiawei |
NCT04683406: A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A |
|
|
| Completed | 3 | 750 | RoW | ZSP1273 600 mg, Placebo to Oseltamivir, Oseltamivir(oral), Placebo to ZSP1273 | Guangdong Raynovent Biotech Co., Ltd | Influenza A | 04/23 | 05/23 | | |
| Recruiting | 2 | 116 | RoW | Placebo, TQA3334 Tablet, Nucleoside (acid) analogs (NAs) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Hepatitis B | 12/25 | 06/26 | | |
NCT05965128: Promotion and Application of a New Three-level Etiological Diagnosis Strategy for Fever Clinics in Respiratory Infectious Diseases |
|
|
| Recruiting | N/A | 1255 | RoW | | Huashan Hospital | Respiratory Infectious Diseases | 12/23 | 12/27 | | |
STAT, NCT05906459: Simplification and Test and Treat Strategies Towards Hepatitis C Eliminationplatform" in China |
|
|
| Recruiting | N/A | 20000 | RoW | Anti-HCV antibody and HCV core antigen testing | Huashan Hospital | Hepatitis C Virus Infection | 12/23 | 06/24 | | |
NCT05855395: The Standard of Care Combined With Glucocorticoid in Elderly People With Mild or Moderate COVID-19 |
|
|
| Recruiting | N/A | 5815 | RoW | Glucocorticoid, dexamethasone, prednisone, methylprednisolone | Huashan Hospital | COVID-19 | 05/24 | 12/24 | | |
NCT05755776: The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment |
|
|
| Recruiting | N/A | 204 | RoW | TMF, Heng Mu | The Second Affiliated Hospital of Chongqing Medical University, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Chronic Hepatitis B | 12/24 | 12/24 | | |
NCT05937178: Real-world Study Optimizing Nucleotide-analogues |
|
|
| Recruiting | N/A | 20000 | RoW | ETV/TAF/TDF/TMF/IFN, ETV/TAF/TDF/TMF | Huashan Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, Beijing YouAn Hospital, Peking University People's Hospital, Peking University First Hospital, Xiamen Hospital of Traditional Chinese Medicine, First Affiliated Hospital of Fujian Medical University, LanZhou University, Third Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, The Affiliated Hospital Of Guizhou Medical University, Hainan General Hospital, Hebei Medical University Third Hospital, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Henan Provincial People's Hospital, The Second Affiliated Hospital of Harbin Medical University, Tongji Hospital, Wuhan Union Hospital, China, Renmin Hospital of Wuhan University, Central South University, Xiangya Hospital of Central South University, The First Hospital of Jilin University, the Second Hospital of Nangjing, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Hospital of Xuzhou Medical University, The First Affiliated Hospital of Nanchang University, Shengjing Hospital, Qingdao Sixth People's Hospital, Shandong Provincial Hospital Affiliated to Shandong First Medical University, The Second Hospital of Shandong University, The First Affiliated Hospital of Shanxi Medical University, Tang-Du Hospital, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, West China Hospital, Tianjin Second People's Hospital, First Affiliated Hospital of Xinjiang Medical University, The First People's Hospital of Yunnan, Shulan (Hangzhou) Hospital, Zhejiang University, Southwest Hospital, China, The Second Affiliated Hospital of Chongqing Medical University, Sichuan Provincial People's Hospital | Hepatitis B, Chronic | 01/29 | 01/29 | | |
NCT05965388: Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy |
|
|
| Not yet recruiting | N/A | 5000 | RoW | nucleoside analogues or interferon | Wen-hong Zhang, Shandong Provincial Hospital Affiliated to Shandong First Medical University, First Affiliated Hospital Xi'an Jiaotong University, The Affiliated Hospital of Xuzhou Medical University, First Affiliated Hospital of Fujian Medical University, The Third People's Hospital of Taiyuan, The First People's Hospital of Yunnan, The First Affiliated Hospital of Anhui Medical University, Wuhan Union Hospital, China, The First Affiliated Hospital with Nanjing Medical University | HBV, HCC | 02/29 | 02/29 | | |
| Yang, Pinting |
| Recruiting | 2 | 146 | RoW | Sirolimus, rapamycin, Placebo | Chinese SLE Treatment And Research Group, Beijing Municipal Science & Technology Commission, North China Pharmaceutical Group Corporation | Systemic Lupus Erythematosus | 10/24 | 05/25 | | |
NCT05212051: Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active AS |
|
|
| Recruiting | 2 | 120 | RoW | JS005, Recombinant humanized anti-IL-17A monoclonal antibody injection, Placebo | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Active Ankylosing Spondylitis | 11/22 | 01/23 | | |
NCT05242588: Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA |
|
|
| Recruiting | 2 | 120 | RoW | JS005, Recombinant humanized anti-IL-17A monoclonal antibody injection, Placebo | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Non-radiographic Axial Spondyloarthritis | 04/23 | 06/23 | | |
NCT05998759: Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia |
|
|
| Recruiting | 2 | 296 | RoW | Telitacicept, recombinant human B lymphocyte stimulating factor receptor-Fc fusion protein, Recombinant Human B Lymphocyte(RC18), Tai'ai®, Placebo, Placebo control, control | Beijing Hospital, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial), Peking University People's Hospital, Peking University Third Hospital, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, Wuhan Union Hospital, China, Second Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The Affiliated Hospital of Inner Mongolia Medical University, First Hospital of China Medical University, Shandong Provincial Hospital, Changhai Hospital, RenJi Hospital, Shanxi Bethune Hospital, West China Hospital, Institute of Hematology & Blood Diseases Hospital, China, Tianjin First Central Hospital, Tianjin Medical University General Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, The First People's Hospital of Yunnan | Connective Tissue Diseases, Thrombocytopenia | 12/25 | 12/25 | | |
